According to the latest research by Persistence Market Research, the Ocular Genetic Diagnostics market is set to witness a growth of 8.5% during the forecast period.
Demand for Ocular Genetic Diagnostics expects to witness stable recovery in the short-term, with a positive growth outlook in the long run. The development and demand for the Ocular Genetic Diagnostics market industry will offer lucrative opportunities for the providers in near future.
There are around 5,000 genetic disorders and syndromes that affect the mankind. Of this vast number, at least one third of them are related to eyes. With the recent advancements in molecular genetics and various sequencing methods, a wide array of various hereditary eye diseases have been discovered. This is one of the major factors that will drive the demand for ocular genetic diagnostics in the forecast period.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32873
In an article published on the Medgenome website on “Ocular Genetics”, it stated that amongst all the cases of blindness amongst infants, 60% cases were inherited in nature, such as congenital cataracts, retinal degeneration, optic atrophy, congenital glaucoma, and eye malformations.
And around 40% of patients with a type of strabismus also showed to have a familial history of the same. With the growing prevalence of ocular genetic disorders, the ocular genetic diagnostics demand outlook is anticipated to experience upsurge in the forecast period.
Furthermore, the increasing awareness regarding the efficiency of molecular genetic testing for various hereditary and chronic disorders affecting the population and increased adoption rates amongst healthcare professionals for early diagnosis of such diseases is expected to favor the growth of Ocular Genetic Diagnostics field in the forthcoming period.
In an article “Technology driving advances in ophthalmology”, in August 2019, the author stated that Optical coherence tomographic (OCT) scanning is the newest technology that uses infrared light interferometry, which works on the similar grounds of ultrasonography, which can be used to produce detailed retinal images within a minimal testing time.
This can be used for the non-invasive diagnosis of various disorders such as neovascular ‘wet’ age related macular degeneration (nAMD) and diabetic macular edema. Furthermore, portable OCT scanners are in pipeline for guiding vitreoretinal surgeons intraoperatively.
The US and Canada regions are expected to show a lower growth during the forecast period due to various factors such as cancellation and indefinite postponement of non-essential diagnostics due to COVID-19 pandemic.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32873
But, some of the favorable government policies and preemptive steps taken to increase the scope of screening amongst the population by the manufacturing companies is anticipated to contribute a little to the growth of this sector in US and Canada regions in the forecast years.
The ocular genetic diagnostic demand in the European region is anticipated to see increased demand and growth because of various initiatives taken by the National Health Scheme England (NHSE).
The initiatives include centralized funding for rare disease testing, a national directory for all the genetic diagnostic tests available for use and the creation of three testing laboratories specifically for ophthalmic genetics.
Some of the major players who provide ocular genetic diagnostic testing are,
- Blueprint Genetics
- Columbia ophthalmology
- Centogene
- DBGen
- Quest Diagnostics
- Medgenome
- Sankara Nethralaya
- Fulgent Genetics
- GeneDx
- Devyser
- Invitae Corporation.
On December 19, 2019, MedGenome, a Bengaluru based diagnostics lab received College of American Pathologists (CAP) accreditation based on the outcomes of on-site inspection. Medgenome is one of the leading genetic testing laboratories, globally and they offer various unique genomic solutions for rare diseases.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32873
Key Segments:
By Gene Panel Tests:
- Corneal Dystrophy Gene Panel
- Bardet-Biedl Syndrome Gene Panel
- Cataract Gene Panel (Congenital/Developmental)
- Choroideremia – CHM gene – Deletion/Duplication
- Congenital Stationary Night Blindness Gene Panel
- Leber Congenital Amaurosis Gene Panel
- Microphthalmia and Anophthalmia Gene Panel
- Optic Atrophy Gene Panel
- RB1 Gene Analysis
- RB1 Gene Deletion/Duplication Analysis
- Retinal Degeneration Gene Panel
- Usher Syndrome (USH2A) Deletion/Duplication Analysis
- Usher Syndrome Gene Panel
By Test Methodologies:
- Next-generation Sequencing (NGS)
- Multiplex Ligation-Dependent Probe Amplification (MLPA)
- Fragment Analysis PCR for Repeat Expansion Analysis
By Test Sample:
- Blood
- Extracted DNA Samples
By Turn Around Times (TAT):
- 21 Working Days for NGS
- 14 Working Days for MLPA
- 21 Working Days for Sanger Sequencing
- 7-14 Working Days for Fragment Analysis
- 8-15 Working Days for Karyotyping
By End –User:
- Hospitals
- Diagnostic Laboratories
- Academic & Research Centers
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
